Eversept Partners, LP Ionis Pharmaceuticals Inc Transaction History

Eversept Partners, LP

$1.26 Billion
Q3 2024

A detailed history of Eversept Partners, LP transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Eversept Partners, LP holds 471,355 shares of IONS stock, worth $16.8 Million. This represents 1.49% of its overall portfolio holdings.

Number of Shares

471,355

Previous 456,881 3.17%

Holding current value

$16.8 Million

Previous $21.8 Million 13.28%

% of portfolio

1.49%

Previous 1.64%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$40.06 - $51.86 $579,828 - $750,621	14,474 Added 3.17%	471,355 $18.9 Million
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $2.93 Million - $3.84 Million	80,443 Added 21.37%	456,881 $21.8 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $2.18 Million - $2.77 Million	51,784 Added 15.95%	376,438 $16.3 Million
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $3.13 Million - $3.73 Million	72,208 Added 28.6%	324,654 $16.4 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $418,649 - $512,491	10,874 Added 4.5%	252,446 $11.5 Million
Q2 2023 Nov 08, 2023	SELL	$34.73 - $43.33 $2.15 Million - $2.68 Million	-61,797 Reduced 20.37%	241,572 $9.91 Million
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $2.15 Million - $2.68 Million	-61,797 Reduced 20.37%	241,572 $9.91 Million
Q1 2023 Nov 08, 2023	BUY	$33.58 - $41.2 $2.1 Million - $2.57 Million	62,394 Added 25.89%	303,369 $10.8 Million
Q1 2023 May 15, 2023	BUY	$33.58 - $41.2 $2.1 Million - $2.57 Million	62,394 Added 25.89%	303,369 $10.8 Million
Q4 2022 Nov 08, 2023	BUY	$37.12 - $46.52 $1.45 Million - $1.82 Million	39,142 Added 19.39%	240,975 $9.1 Million
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $1.45 Million - $1.82 Million	39,142 Added 19.39%	240,975 $9.1 Million
Q3 2022 Nov 08, 2023	BUY	$36.54 - $48.66 $4.22 Million - $5.62 Million	115,522 Added 133.84%	201,833 $8.93 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $4.22 Million - $5.62 Million	115,522 Added 133.84%	201,833 $8.93 Million
Q2 2022 Nov 08, 2023	SELL	$31.71 - $43.0 $2.3 Million - $3.12 Million	-72,495 Reduced 45.65%	86,311 $3.2 Million
Q2 2022 Aug 15, 2022	SELL	$31.71 - $43.0 $2.3 Million - $3.12 Million	-72,495 Reduced 45.65%	86,311 $3.2 Million
Q1 2022 Nov 08, 2023	SELL	$29.88 - $37.04 $2.47 Million - $3.07 Million	-82,766 Reduced 34.26%	158,806 $5.88 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $6.75 Million - $8.37 Million	-225,983 Reduced 58.73%	158,806 $5.88 Million
Q4 2021 Nov 08, 2023	SELL	$25.61 - $35.1 $1.68 Million - $2.31 Million	-65,712 Reduced 14.59%	384,789 $11.7 Million
Q4 2021 Feb 14, 2022	SELL	$25.61 - $35.1 $1.68 Million - $2.31 Million	-65,712 Reduced 14.59%	384,789 $11.7 Million
Q3 2021 Nov 08, 2023	BUY	$33.54 - $40.55 $285,123 - $344,715	8,501 Added 1.92%	450,501 $15.1 Million
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $285,123 - $344,715	8,501 Added 1.92%	450,501 $15.1 Million
Q2 2021 Nov 08, 2023	BUY	$34.54 - $47.25 $6.92 Million - $9.47 Million	200,428 Added 82.97%	442,000 $17.6 Million
Q2 2021 Aug 16, 2021	BUY	$34.54 - $47.25 $15.3 Million - $20.9 Million	442,000 New	442,000 $17.6 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.06B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account

Eversept Partners, LP Ionis Pharmaceuticals Inc Transaction History